Perioperative Trastuzumab, Capecitabine, and Oxaliplatin in Patients With HER2+ Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Perioperative Trastuzumab, Capecitabine and Oxaliplatin in Patients With HER2-Positive Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma: NEOHX Phase II Trial
Eur. J. Cancer 2021 Mar 01;145(xx)158-167, F Rivera, M Izquierdo-Manuel, P García-Alfonso, E Martínez de Castro, J Gallego, ML Limón, M Alsina, L López, M Galán, E Falcó, JL Manzano, E González, N Muñoz-Unceta, C López, E Aranda, E Fernández, M Jorge, P Jiménez-FonsecaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.